2021
Presence of complete murine viral genome sequences in patient-derived xenografts
Yuan Z, Fan X, Zhu J, Fu T, Wu J, Xu H, Zhang N, An Z, Zheng W. Presence of complete murine viral genome sequences in patient-derived xenografts. Nature Communications 2021, 12: 2031. PMID: 33795676, PMCID: PMC8017013, DOI: 10.1038/s41467-021-22200-5.Peer-Reviewed Original ResearchConceptsPatient-derived xenograftsViral infectionMurine viral infectionHigh virus loadDrug developmentDrug metabolism-related genesVirus loadXenograft experimentsMetabolism-related genesXenograftsUnbiased data-driven approachTumor cellsInfectionExpression levelsEntire viral genomeViral genome sequencesViral sequencesViral genomeCancerImmune
2012
Data mining methodologies for pharmacovigilance
Liu M, Matheny M, Hu Y, Xu H. Data mining methodologies for pharmacovigilance. ACM SIGKDD Explorations Newsletter 2012, 14: 35-42. DOI: 10.1145/2408736.2408742.Peer-Reviewed Original ResearchAdverse drug reactionsElectronic medical recordsLong-term adverse drug reactionsTerm adverse drug reactionPrevention of ADRsAdverse drug eventsPatient-reported dataPotential adverse drug reactionsNational surveillance systemEmergency departmentDrug eventsDrug reactionsPreclinical dataMedical recordsADR monitoringClinical trialsMedication safetyPreclinical characteristicsSpontaneous reportsPostmarketing phaseOnline health forumsPostmarketing stageDrug developmentHealth forumsPre-marketing stagesLarge-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs
Liu M, Wu Y, Chen Y, Sun J, Zhao Z, Chen X, Matheny M, Xu H. Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs. Journal Of The American Medical Informatics Association 2012, 19: e28-e35. PMID: 22718037, PMCID: PMC3392844, DOI: 10.1136/amiajnl-2011-000699.Peer-Reviewed Original ResearchConceptsAdverse drug reactionsPost-marketing phaseDrug reactionsSevere adverse drug reactionsImportant adverse drug reactionsWithdrawal of rofecoxibPotential adverse drug reactionsPost-marketing surveillanceADR predictionPatient morbidityClinical trialsMajor causeLarge-scale studiesDrugsMolecular pathwaysDrug developmentPhenotypic featuresSignificant improvementPhenotypic characteristicsEarly stages